377 results on '"Sternberg C"'
Search Results
2. Dosierung, Sicherheit und Pharmakokinetik der Kombinationstherapie mit Darolutamid (DARO), Androgendeprivationstherapie (ADT) und Docetaxel (DOC) bei Patienten mit metastasiertem hormonsensitivem Prostatakarzinom (mHSPC) in der ARASENS Studie
3. Effizienz und Sicherheit von Darolutamid (DARO) in Kombination mit Androgendeprivationstherapie (ADT) und Docetaxel (DOC) nach Krankheitsvolumen und -risiko in der Phase 3 ARASENS Studie
4. Lebensqualität und Patienten-relevante Endpunkte unter Darolutamid-Therapie in der Phase-3-Studie ARASENS
5. The architecture of political representation. A historiographical review
6. 1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)
7. 1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study
8. LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)
9. 1746P Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)
10. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)
11. A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy
12. Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
13. B19 - Patient (pt) characteristics and treatment patterns in the radium (Ra)-223 REASSURE observational study
14. Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy
15. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL
16. The use of biosimilar medicines in oncology--position statement of the Brazilian Society of Clinical Oncology (SBOC)
17. Radiotherapy modulates expression of EGFR, ERCC1 and p53 in cervical cancer
18. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
19. The Skull of Leidyosuchus canadensis Lambe
20. The Systematic Position of Trachodon
21. Pachycephalosauridae Proposed for Dome-Headed Dinosaurs, Stegoceras lambei, n. sp., Described
22. Thescelosaurus edmontonensis, n. sp., and Classification of the Hypsilophodontidae
23. Ceratopsidae from Alberta
24. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
25. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multi-center international trial.
26. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
27. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
28. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial†
29. Erratum: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (Annals of Oncology (2018) 29(2) (361–369), (S0923753419350392), (10.1093/annonc/mdx692))
30. P12.02 Implementation of a Timeliness-of-care Pathway System for Lung Cancer Patients in a Private Outpatient Oncology Service.
31. Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study
32. Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study
33. Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study
34. Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study
35. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy†
36. Novel hormonal therapy for castration-resistant prostate cancer
37. Quantification of biofilm structures by the novel computer program COMSTAT
38. Plasma gene conversions after one cycle (C) abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): A biomarker analysis of a multi-centre, international trial
39. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
40. Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study
41. Expanding the boundaries of clinical practice: building on experience with targeted therapies
42. Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer
43. Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate: A Randomized, Open-Label Phase 2 Study
44. Applikation eines neuen Polyester-Patches bei Rekonstruktion von Rotatorenmanschetten-Massenrupturen verbessert das klinische Ergebnis und Sehnenintegrität signifikant
45. Muscle invasive and metastatic bladder cancer
46. Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab
47. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
48. Irinotecan chemotherapy associated with transient dysarthria and aphasia
49. Monoclonius from Southeastern Alberta Compared with Centrosaurus
50. Neo-adjuvant and adjuvant chemotherapy of bladder cancer: Is there a role?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.